EBITDA grew 85 per cent QoQ to Rs 1,432 million
OneSource Specialty Pharma announced the consolidated financial results for the quarter (Q3FY25) ended December 31, 2024.
Q3FY25 Performance Highlights
· Revenues of Rs 3,926 million grew 18 per cent QoQ.
· EBITDA grew 85 per cent QoQ to Rs 1,432 million.
· EBITDA margin of 36.5 per cent grew by 1,334 basis points QoQ.
· Q3 FY25 normalised PAT was Rs 898 million, resulting in an EPS of Rs 7.8 for the quarter.
Neeraj Sharma, CEO, OneSource Specialty Pharma said, “We are off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we are on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We are committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.”
